Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 107.55 USD -0.58% Market Closed
Market Cap: $266.9B

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is hidden USD. Compared to the current market price of 107.55 USD, Merck & Co Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
267.6B USD 4.2 14.1 10 11.8
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
US
Johnson & Johnson
NYSE:JNJ
530.8B USD 5.6 19.8 13.8 17
CH
Roche Holding AG
SIX:ROG
279.4B CHF 4.5 29.6 12.6 14.7
UK
AstraZeneca PLC
LSE:AZN
214.1B GBP 5 30.8 20 29.3
CH
Novartis AG
SIX:NOVN
224.2B CHF 5.1 19.7 15.8 20.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17.1 11.9 13.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.1B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
96.7B EUR 1.5 7 6.4 6.4
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD 2.3 18.5 6.7 8.7
P/E Multiple
Earnings Growth PEG
US
Merck & Co Inc
NYSE:MRK
Average P/E: 22.6
14.1
14%
1
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
38%
0.8
CH
Novartis AG
SIX:NOVN
19.7
17%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
17.1
2%
8.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
7
25%
0.3
US
Bristol-Myers Squibb Co
NYSE:BMY
18.5
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBITDA: 44.2
10
6%
1.7
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.6
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20
10%
2
CH
Novartis AG
SIX:NOVN
15.8
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
1%
11.9
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
6.7
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBIT: 94.2
11.8
8%
1.5
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.7
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.3
23%
1.3
CH
Novartis AG
SIX:NOVN
20.3
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
10%
0.9